A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Market Place (formerly Market Place by Jasons, Jason's Food & Living, and Jasons ichiba) in Hong Kong is a high-end supermarket chain owned by DFI Retail Group. The chain also has a joint venture in mainland China with Beijing Hualian Group called BHG Market Place and formerly ran stores (Jasons Market Place) in Taiwan until they were sold to Carrefour. The Malaysian chain called Mercató (formerly Jasons Food Hall) is owned by Macrovalue Sdn Bhd. after its acquisition of DFI Malaysian food retailing business in 2023. Cold Storage Fresh (formerly Market Place, Jasons, and Jasons Deli) in Singapore is also owned by Macrovalue Sdn Bhd since 2025. The Marketplace (formerly Market Place by Rustan's) in the Philippines has been owned by Robinsons Retail Holdings since 2018, before which it was owned by Rustan Supercenters. DFI also operates further similar supermarkets under the 3hreeSixty and Oliver's The Delicatessen brands in Hong Kong and other supermarkets around Asia with Wellcome.
Drum drying is a method used for drying out liquids from raw materials with a drying drum. In the drum-drying process, pureed raw ingredients are dried at relatively low temperatures over rotating, high-capacity drums that produce sheets of drum-dried product. This product is milled to a finished flake or powder form. Modern drum drying techniques results in dried ingredients which reconstitute immediately and retain much of their original flavor, color and nutritional value. Some advantages of drum drying include the ability to dry viscous foods which cannot be easily dried with other methods. Drum dryers are easy to operate and maintain. Other products where drum drying can be used are, for example, starches, breakfast cereals, baby food, and instant mashed potatoes to make them cold-water-soluble.
expedited border control programme for low-risk travellers holding Canadian or U.S. citizenship or permanent residence. Membership requires approval by Canadian and U.S. authorities and entitles members to dedicated RFID-enabled lanes when crossing the land border. A NEXUS card can also be utilised as a travel document between the two countries and entitles passengers to priority border control facilities in Canada and Global Entry facilities in the U.S. Free and Secure Trade (FAST) is a similar programme for commercial drivers and approved importers, reducing the amount of customs checks conducted at the border and expediting the border control process. When entering the U.S. by air, holders of NEXUS cards may use Global Entry kiosks to clear border controls at participating airports SENTRI: SENTRI is a programme similar to NEXUS for U.S. and Mexican citizens that also allows members to register their cars for expedited land-border controls. Unlike NEXUS, SENTRI is administered solely by the American government and does not provide expedited controls when entering Mexico. When entering the United States by land from Canada, a NEXUS card can be used, but not the other way around. Individuals holding a NEXUS card may additionally register their cars for expedited land border controls under SENTRI. When entering the United States by air, holders of SENTRI cards may use Global Entry kiosks to clear border controls at participating airports
Sources: en.wikipedia.org
=== Subcellular localization === The c1orf27 protein is likely cytoplasmic. This was found with 55.5 reliability. The K-NN prediction was k = 9/23 and the protein was found to be 55.6% cytoplasmic, 11.1% mitochondrial, 11.1% vacuolar, 11.1% cytoskeletal, and 11.1% golgi.
==== Distribution of inefficient medicine and harms to health ==== One of the first acts under Melo's administration was to buy, among other medicines, azithromycin, ivermectin, and hydroxychloroquine and chloroquine – the latter of two which had been approved for the treatment of malaria – to supposedly combat COVID-19, despite multiple studies showing that all the medicines bought were ineffective towards treating the virus. The controversial decision was brought to suit by PSOL, which alleged that his administration was using public money to buy the medicine. The measure was also criticized by the council of the Faculty of Medicine at the Federal University of Rio Grande do Sul that asked for the immediate suspension of their distribution. Melo justified the purchase with the Ministry of Medicine by stating that people in the middle and upper-middle classes, and their friends, were taking the medicine. In total, the city government bought 239,000 reais worth of the medications, which they packaged into what they called the "COVID kit". Along with their ineffectiveness, it has been reported that the use of the medications combined over a long period and in high doses could lead to liver and renal damage, leading to the need for a liver transplant or possibly death. In February, the Justice ministry prohibited, in a liminary decision, the city from distributing the kit. In the decision, the judge argued that the prohibition would be necessary while robust evidence, based on clinical studies and recognized by the scientific community, did not exist.
Lethal injection dosage: 100 mEq (milliequivalents) Potassium is an electrolyte, 98% of which is intracellular. The 2% remaining outside the cell has great implications for cells that generate action potentials. Doctors prescribe potassium for patients when potassium levels in the blood are insufficient, called hypokalemia. The potassium can be given orally, which is the safest route, or it can be given intravenously, in which case strict rules and hospital protocols govern the rate at which it is given. The usual intravenous dose of 10–20 mEq per hour is given slowly since it takes time for the electrolyte to equilibrate into the cells. When used in a state-sanctioned lethal injection, a bolus potassium injection affects the electrical conduction of heart muscle and ultimately leads to cardiac arrest. The potassium bolus used in lethal injection quickly raises the level of potassium outside the heart muscle cells, causing a condition called hyperkalemia, which disrupts the normal electrical activity of the heart, especially affecting the cells that control the heartbeat. However, potassium's effect on membrane potential is concentration dependent and ultimately occurs in two phases.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.